Herantis Pharma Plc's board decides on new option rights program for managing director, management team and other key personnel
Herantis Pharma PlcCompany release, 15 September 2022 at 3:30 p.m. EEST The Board of Directors of Herantis Pharma Plc ("Herantis") has on 12 September 2022 decided on a new option rights program 2022 I based on the authorization granted by the Annual General Meeting held on 21 April 2022. Under the new option rights program 2022 I, in aggregate up to 200,000 option rights entitling to shares may be issued to the CEO of Herantis, management team members, and other key personnel. There is a weighty financial reason to issue the option rights as they will be offered to management team